Logo image of ALMKS.PA

MAKING SCIENCE GROUP SA (ALMKS.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:ALMKS - ES0105463006 - Common Stock

8.5 EUR
+0.4 (+4.94%)
Last: 12/19/2025, 7:00:00 PM
Fundamental Rating

2

ALMKS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 66 industry peers in the Media industry. Both the profitability and financial health of ALMKS have multiple concerns. ALMKS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

ALMKS had negative earnings in the past year.
In the past year ALMKS had a positive cash flow from operations.
ALMKS had negative earnings in 4 of the past 5 years.
Of the past 5 years ALMKS 4 years had a positive operating cash flow.
ALMKS.PA Yearly Net Income VS EBIT VS OCF VS FCFALMKS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -0.99%, ALMKS is doing worse than 64.62% of the companies in the same industry.
ALMKS has a worse Return On Equity (-6.62%) than 64.62% of its industry peers.
The Return On Invested Capital of ALMKS (7.51%) is better than 67.69% of its industry peers.
Industry RankSector Rank
ROA -0.99%
ROE -6.62%
ROIC 7.51%
ROA(3y)-2.49%
ROA(5y)-1.44%
ROE(3y)-23.01%
ROE(5y)-9.95%
ROIC(3y)N/A
ROIC(5y)N/A
ALMKS.PA Yearly ROA, ROE, ROICALMKS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 100 150

1.3 Margins

ALMKS has a worse Operating Margin (1.86%) than 61.54% of its industry peers.
In the last couple of years the Operating Margin of ALMKS has declined.
ALMKS has a Gross Margin of 20.80%. This is amonst the worse of the industry: ALMKS underperforms 80.00% of its industry peers.
In the last couple of years the Gross Margin of ALMKS has declined.
Industry RankSector Rank
OM 1.86%
PM (TTM) N/A
GM 20.8%
OM growth 3YN/A
OM growth 5Y-6.4%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.93%
GM growth 5Y-5%
ALMKS.PA Yearly Profit, Operating, Gross MarginsALMKS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 10 20

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ALMKS is still creating some value.
Compared to 1 year ago, ALMKS has more shares outstanding
Compared to 5 years ago, ALMKS has more shares outstanding
The debt/assets ratio for ALMKS has been reduced compared to a year ago.
ALMKS.PA Yearly Shares OutstandingALMKS.PA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
ALMKS.PA Yearly Total Debt VS Total AssetsALMKS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

ALMKS has an Altman-Z score of 1.73. This is a bad value and indicates that ALMKS is not financially healthy and even has some risk of bankruptcy.
ALMKS has a Altman-Z score of 1.73. This is comparable to the rest of the industry: ALMKS outperforms 60.00% of its industry peers.
The Debt to FCF ratio of ALMKS is 1140.00, which is on the high side as it means it would take ALMKS, 1140.00 years of fcf income to pay off all of its debts.
ALMKS has a worse Debt to FCF ratio (1140.00) than 67.69% of its industry peers.
A Debt/Equity ratio of 0.46 indicates that ALMKS is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.46, ALMKS is in the better half of the industry, outperforming 67.69% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 1140
Altman-Z 1.73
ROIC/WACC1.1
WACC6.85%
ALMKS.PA Yearly LT Debt VS Equity VS FCFALMKS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 0.76 indicates that ALMKS may have some problems paying its short term obligations.
The Current ratio of ALMKS (0.76) is worse than 70.77% of its industry peers.
ALMKS has a Quick Ratio of 0.76. This is a bad value and indicates that ALMKS is not financially healthy enough and could expect problems in meeting its short term obligations.
ALMKS has a Quick ratio of 0.73. This is in the lower half of the industry: ALMKS underperforms 66.15% of its industry peers.
Industry RankSector Rank
Current Ratio 0.76
Quick Ratio 0.73
ALMKS.PA Yearly Current Assets VS Current LiabilitesALMKS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 61.58% over the past year.
Looking at the last year, ALMKS shows a quite strong growth in Revenue. The Revenue has grown by 16.22% in the last year.
ALMKS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 51.26% yearly.
EPS 1Y (TTM)61.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-323.33%
Revenue 1Y (TTM)16.22%
Revenue growth 3Y35.39%
Revenue growth 5Y51.26%
Sales Q2Q%21.45%

3.2 Future

ALMKS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.62% yearly.
ALMKS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.10% yearly.
EPS Next Y-27.27%
EPS Next 2Y11.46%
EPS Next 3Y15.62%
EPS Next 5YN/A
Revenue Next Year33.94%
Revenue Next 2Y25.99%
Revenue Next 3Y22.1%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ALMKS.PA Yearly Revenue VS EstimatesALMKS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
ALMKS.PA Yearly EPS VS EstimatesALMKS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0.1 0.2 0.3 0.4 0.5

0

4. Valuation

4.1 Price/Earnings Ratio

ALMKS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 34.72, which means the current valuation is very expensive for ALMKS.
63.08% of the companies in the same industry are cheaper than ALMKS, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.84, ALMKS is valued a bit more expensive.
Industry RankSector Rank
PE N/A
Fwd PE 34.72
ALMKS.PA Price Earnings VS Forward Price EarningsALMKS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ALMKS indicates a slightly more expensive valuation: ALMKS is more expensive than 61.54% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ALMKS indicates a slightly more expensive valuation: ALMKS is more expensive than 67.69% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 1526.6
EV/EBITDA 9.28
ALMKS.PA Per share dataALMKS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

ALMKS's earnings are expected to grow with 15.62% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.46%
EPS Next 3Y15.62%

0

5. Dividend

5.1 Amount

No dividends for ALMKS!.
Industry RankSector Rank
Dividend Yield 0%

MAKING SCIENCE GROUP SA

EPA:ALMKS (12/19/2025, 7:00:00 PM)

8.5

+0.4 (+4.94%)

Chartmill FA Rating
GICS IndustryGroupMedia & Entertainment
GICS IndustryMedia
Earnings (Last)07-31 2025-07-31
Earnings (Next)N/A N/A
Inst Owners3.56%
Inst Owner ChangeN/A
Ins Owners61.03%
Ins Owner ChangeN/A
Market Cap76.33M
Revenue(TTM)274.00M
Net Income(TTM)-1.72M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-44.19%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 34.72
P/S 0.28
P/FCF 1526.6
P/OCF 231.3
P/B 2.94
P/tB N/A
EV/EBITDA 9.28
EPS(TTM)-0.2
EYN/A
EPS(NY)0.24
Fwd EY2.88%
FCF(TTM)0.01
FCFY0.07%
OCF(TTM)0.04
OCFY0.43%
SpS30.51
BVpS2.9
TBVpS-4.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.99%
ROE -6.62%
ROCE 10.22%
ROIC 7.51%
ROICexc 13.46%
ROICexgc N/A
OM 1.86%
PM (TTM) N/A
GM 20.8%
FCFM 0.02%
ROA(3y)-2.49%
ROA(5y)-1.44%
ROE(3y)-23.01%
ROE(5y)-9.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y-6.4%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.93%
GM growth 5Y-5%
F-Score6
Asset Turnover1.58
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 1140
Debt/EBITDA 1.03
Cap/Depr 4.29%
Cap/Sales 0.1%
Interest Coverage 1.14
Cash Conversion 2.84%
Profit Quality N/A
Current Ratio 0.76
Quick Ratio 0.73
Altman-Z 1.73
F-Score6
WACC6.85%
ROIC/WACC1.1
Cap/Depr(3y)13.72%
Cap/Depr(5y)311.76%
Cap/Sales(3y)0.4%
Cap/Sales(5y)7.85%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-323.33%
EPS Next Y-27.27%
EPS Next 2Y11.46%
EPS Next 3Y15.62%
EPS Next 5YN/A
Revenue 1Y (TTM)16.22%
Revenue growth 3Y35.39%
Revenue growth 5Y51.26%
Sales Q2Q%21.45%
Revenue Next Year33.94%
Revenue Next 2Y25.99%
Revenue Next 3Y22.1%
Revenue Next 5YN/A
EBIT growth 1Y278.77%
EBIT growth 3YN/A
EBIT growth 5Y41.58%
EBIT Next Year200%
EBIT Next 3Y56.86%
EBIT Next 5YN/A
FCF growth 1Y103.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y178.57%
OCF growth 3Y-64.23%
OCF growth 5YN/A

MAKING SCIENCE GROUP SA / ALMKS.PA FAQ

What is the fundamental rating for ALMKS stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALMKS.PA.


What is the valuation status of MAKING SCIENCE GROUP SA (ALMKS.PA) stock?

ChartMill assigns a valuation rating of 0 / 10 to MAKING SCIENCE GROUP SA (ALMKS.PA). This can be considered as Overvalued.


What is the profitability of ALMKS stock?

MAKING SCIENCE GROUP SA (ALMKS.PA) has a profitability rating of 1 / 10.


What is the financial health of MAKING SCIENCE GROUP SA (ALMKS.PA) stock?

The financial health rating of MAKING SCIENCE GROUP SA (ALMKS.PA) is 2 / 10.